Abstract:
A coil-type vasoocclusion device (10) for establishing an embolus or vascular occlusion in a human or veterinary patient is adapted for introduction into the patient via a catheter (32). The device (10) first includes a coil (12) having proximal and distal coil ends (16,18) and a coil lumen (20). The device (10) also includes a core (22) disposed in at least part of the coil lumen (20), the core having proximal and distal core ends (24,26). Only one core end (24 or 26) is directly affixed to a respective end (16 or 18) of the coil (12); the other core end (26 or 24) is not directly connected to either end (16 or 18) of the coil (12). The core (22) is preferably nitinol in a superelastic state, being in other than its stress induced, martensitic condition. The device (10) can include a thrombogenic material (38) connected to or carried by the coil (12). The coil (12) is preferably adapted to achieve a suitable secondary shape (60) when deployed from the catheter (32). A medical device (40) combining the catheter (32), a pusher (34), a coupling (30) and the vasoocclusion device (10) is also disclosed. The vasoocclusion device (10) is easily repositioned in the vascular system, thereby ensuring proper deployment, and also enjoys a dislodging force about twice as great as comparable coil-type devices lacking the core (22), substantially or completely preventing migration of the device (10) after its deployment.
Abstract:
Amorphous SiOx (SiO2), SiONx, silicon nitride (Si3N4), surface treatments are provided, on both metal (titanium) and non-metal surfaces. Amorphous silicon-film surface treatments are shown to enhance osteoblast and osteoblast progenitor cell bioactivity, including biomineral formation and osteogenic gene panel expression, as well as enhanced surface hydroxyapatite (HA) formation. A mineralized tissue interface is provided using the amorphous silicon-based surface treatments in the presence of osteoblasts and provides improved bone cell generation/repair and improved interface for secure attachment/bonding to bone. Methods for providing PEVCD-based silicon overlays onto surfaces are provided. Methods of increasing antioxidant enzyme (e.g., superoxide dismutase) expression at a treated surface for enhanced healing are also provided. Continuous generation and release of Si4+ ion into an in vitro or in vivo environment in the presence of osteoblasts/osteoblast progenitor cells, methods of employing same for enhancing the rate of bone healing/bone regeneration, is also described.
Abstract:
The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
Abstract:
A method of forming titanium boron alloys includes forming a mixture of elemental titanium with elemental boron and heating the mixture with a laser, wherein a power level of the laser is set such that reaction of the elemental titanium with the elemental boron to form a titanium-boron alloy is initiated and self-sustaining.
Abstract:
Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Abstract:
Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
Abstract:
The present invention is a system, method for accessing domains of information to identify heretofore unknown relationships between disparate sources of data to seek and obtain knowledge, the invention includes a source of data with one or more domains of information, an Object-Relationship Database for integrating objects from one or more domains of information and a knowledge discovery engine where relationships between two or more objects are identified, retrieved, grouped, ranked, filtered and numerically evaluated.
Abstract:
The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.